BSH 2017 | Potential second-line treatment for indolent lymphoma

Christopher Fox

Christopher Fox, MBChB, MRCP, FRCPath from Nottingham University Hospitals, Nottingham, UK discusses the treatment response for indolent lymphoma and the latest data produced from the GADOLIN study (NCT01059630). There is a poor prognosis for indolent lymphoma patients, especially follicular lymphoma, that fail first-line therapy. This is a major unmet need as the patient outcome for this cohort is extremely dismal. The GADOLIN study assessed the combination of obinutuzumab and bendamustine as second-line therapy for these patients, and the results have indicated that patients treated with the combination of both drugs have a better survival outcome, than patients treated with bendamustine alone. This interview was recorded at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video